Spyglass Capital Management LLC Sells 13,420 Shares of Medpace Holdings, Inc. $MEDP

Spyglass Capital Management LLC cut its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 55,755 shares of the company’s stock after selling 13,420 shares during the quarter. Medpace accounts for approximately 1.9% of Spyglass Capital Management LLC’s investment portfolio, making the stock its 24th largest position. Spyglass Capital Management LLC’s holdings in Medpace were worth $26,773,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. AQR Capital Management LLC increased its position in Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after purchasing an additional 211,411 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Medpace by 158.6% in the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after buying an additional 183,645 shares in the last quarter. Norges Bank purchased a new position in shares of Medpace in the 4th quarter worth $102,156,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Medpace by 92.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after buying an additional 166,654 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of recent research reports. Robert W. Baird lifted their target price on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Truist Financial raised their price target on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Barclays set a $600.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Two equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $584.18.

Insider Transactions at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.50% of the stock is currently owned by insiders.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $570.97 on Wednesday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The firm has a 50-day simple moving average of $498.48 and a two-hundred day simple moving average of $493.41. The company has a market cap of $15.94 billion, a P/E ratio of 33.47, a PEG ratio of 2.63 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the prior year, the firm posted $3.10 earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 17.55 EPS for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.